FDA Approved: ADCETRIS — Supplemental Application (SEAGEN INC.)

View source ↗

Summary

The FDA approved a supplemental application for ADCETRIS (brentuximab vedotin) submitted by Seagen Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma
• Systemic Anaplastic Large Cell Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

SUPPL AP for ADCETRIS (BRENTUXIMAB VEDOTIN)